The share of new prescriptions written for the cholesterol-lowering drug Lipitor surged during the past week as the Pfizer Inc. (NYSE:PFE - News) blockbuster got a boost from a big study showing it was better than Bristol-Myers Squibb Co. (NYSE:BMY - News)'s Pravachol in preventing heart attacks, Thursday’s Wall Street Journal reported.
